NOV 2·SEC EDGARLow
Munsch Frederick sold $2.3M of BLCO
Munsch Frederick (SVP, Controller and CAO) sold 112,015 shares of Bausch & Lomb Corp (BLCO) at $20.48 ($2.29M total) on 2026-10-29.
StockNYSE · US · USDHealthcare · Medical Instruments & Supplies
$BLCO
Bausch & Lomb Corp
Bausch & Lomb is an integrated eye health business serving patients, consumers, physicians and other eye care professionals around the world. Its portfolio includes approximately 400 products across Vision Care, Pharmaceuticals and Surgical. Vision Care includes contact lenses, lens care products, OTC eye drops and nutritional supplements. Pharmaceuticals includes proprietary and generic medicines for eye conditions and post-operative treatment. Surgical offers intraocular lenses, equipment, consumables and instruments for eye procedures. Bausch & Lomb makes and sells these products through its global research, development, manufacturing and commercial operations. Its products include the Biotrue, Bausch + Lomb ULTRA, XIIDRA, MIEBO, enVista and Stellaris Elite brands. The business has approximately 13,000 employees and a presence in approximately 100 countries. Bausch & Lomb is headquartered in Vaughan, Ontario, Canada.
AlphAI earnings readthird quarter of 2026 · OCT 28Bausch + Lomb Posts Strong Third-Quarter Performance, Raises Full-Year 2026 GuidanceVerdict: strongRead →
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Price · $BLCOvia TradingView
AI sentiment · 7d19 articles
- Bullish
- 16
- Neutral
- 3
- Bearish
- 0
Insider · 30dAll trades →
- Buys
- — 0 txs
- Sells
- $2.3M 1 txs
Munsch Frederick1× · $2.3M
10b5-1 share of filings0%
Top stories · $BLCOMore →
OCT 29·tradingview.com
JP Morgan maintains Bausch & Lomb at Neutral, raises price target to $22 from $16
JP Morgan kept its Neutral rating on Bausch & Lomb but raised its price target to $22 from $16, citing a 7.8% upside from the Oct 29 close. Recent analyst price targets for the company range from $19 to $24.
OCT 28·SEC EDGAR 8-K
Bausch & Lomb Corp (BLCO): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Bausch & Lomb Corp (BLCO) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On October 28, 2026, Nathalie Bernier notified Bausch + Lomb Corporation (the “Company”) of her decision to resign from the
BLCO sentiment & insider activity
Over the past 7 days, AlphAI's AI scored 19 news stories mentioning BLCO (Bausch & Lomb Corp). Coverage has skewed bullish: 16 bullish, 3 neutral, and 0 bearish.
Recent BLCO coverage spans financial news, earnings and corporate actions.
In the last 30 days, BLCO insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($2.3M). The most active reporter was Munsch Frederick, SVP, Controller and CAO, with 1 filing.
What's driving BLCO
The insider sale may signal reduced confidence and could pressure the stock.
A higher analyst price target can support near-term sentiment, but the Neutral rating limits conviction and follow-through.
Board vacancy and compensation change may cause modest share pressure.
Raised guidance suggests stronger earnings outlook, likely supporting the stock.
Guidance beat suggests stronger earnings outlook, likely prompting buying interest.
AlphAI scores every news story that mentions BLCO with an AI model for sentiment and relevance, and aggregates insider trades from Bausch & Lomb Corp's SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $BLCO
Score
Munsch Frederick sold $2.3M of BLCO
Munsch Frederick (SVP, Controller and CAO) sold 112,015 shares of Bausch & Lomb Corp (BLCO) at $20.48 ($2.29M total) on 2026-10-29.
1 min read
JP Morgan maintains Bausch & Lomb at Neutral, raises price target to $22 from $16
JP Morgan kept its Neutral rating on Bausch & Lomb but raised its price target to $22 from $16, citing a 7.8% upside from the Oct 29 close. Recent analyst price targets for the company range from $19 to $24.
1 min readBausch & Lomb Corp (BLCO): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Bausch & Lomb Corp (BLCO) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On October 28, 2026, Nathalie Bernier notified Bausch + Lomb Corporation (the “Company”) of her decision to resign from the
1 min readBausch + Lomb Posts Strong Third-Quarter Performance, Raises Full-Year 2026 Guidance
Bausch & Lomb Corp (BLCO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Bausch + Lomb Posts Strong Third-Quarter Performance, Raises Full-Year 2026 Guidance • Revenue of $1.375 Billion • Revenue Grew 7% as Reported and 8% on a Constant Currency 1 Basis Compared to the Third Quarter of 2025 • GAAP Net Income Attributable to Bausch + Lomb
2 min readBausch + Lomb raises 2026 guidance as Q3 revenue grows (BLCO:NYSE)
Bausch + Lomb reported Q3 Non-GAAP EPS of $0.34, exceeding estimates by $0.12. Revenue grew 7.8% year-over-year to $1.38 billion, also beating forecasts. The company raised its 2026 guidance, targeting revenue of $5.45 billion to $5.55 billion and adjusted EBITDA of $1.09 billion to $1.14 billion, excluding acquired IPR&D.
1 min read
Billionaire Investor Took a Stake in Bausch + Lomb Before Its CEO Shake-Up
Dan Loeb's Third Point acquired an 85,000-share stake in Bausch + Lomb (BLCO) valued at $1.4M. The company appointed Thomas J. Appio as interim CEO and expects to raise 2026 EBITDA guidance. Analysts have mixed views, with a consensus price target of $21.67. BLCO stock has outperformed its sector recently but trails peer averages.
2 min readBausch & Lomb Corp (BLCO): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Bausch & Lomb Corp (BLCO) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 Bausch + Lomb and Bausch Health Announce Appointment of Thomas J. Appio as Interim Bausch + Lomb CEO, Expect to Raise Full-Year 2026 Guidance VAUGHAN, Ontario, Oct. 12, 2026 – Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company, and its pa
2 min readBausch + Lomb Stock Rises 9% As Interim CEO Takes Over And 2026 Guidance Is Raised
Bausch + Lomb (BLCO) fell 9.13% to $15.72 after appointing Thomas J. Appio as interim CEO. Brent Saunders departed following a mutual agreement. The company also raised its 2026 adjusted EBITDA guidance, citing strong Q3 performance. Shares have traded between $14.39 and $18.92 in the past year.
2 min readRBC Capital reiterates Bausch & Lomb stock rating on DED momentum
RBC Capital reiterated an Outperform rating and $21.00 price target on Bausch & Lomb (NYSE:BLCO), projecting Q3 2026 revenue of $1,375M and adjusted EBITDA of $275M. The company reported Q2 2026 revenue of $1.394B, up 9.1% YoY, and raised full-year guidance. Analysts predict 2026 EPS of $0.82. Key focus areas include dry eye disease treatments and upcoming product launches.
2 min readBausch + Lomb Advances Oral Therapy for Dry AMD, Ticker BLCO
Bausch + Lomb Corp (BLCO) announced progress in developing BL1243, an oral treatment for dry age-related macular degeneration, following a positive FDA meeting. The company plans to start clinical trials in 2027. BLCO's P/S ratio is 1.18, below its historical median, and it has a GF Score of 60/100, indicating mixed financial health. Insider activity and guru holdings show balanced sentiment.
2 min read